BGLC
BioNexus Gene Lab·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 0
Bearish signal 1
MACD Death Cross
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About BGLC
Bionexus Gene Lab Corp.
A well-known wholesaler of chemical raw materials in Southeast Asia
Unit A-28-7, Level 28, Tower A, Menara UOA Bangsar, No.5 Jln Bangsar Utama 1, Kuala Lumpur, Malaysia 59000
--
BioNexus Gene Lab Corp. was incorporated in Wyoming on May 12, 2017. BioNexus Gene Lab Corp., through the company's wholly-owned subsidiary Chemrex Corporation Sdn.Bhd., focuses on the sale of chemical raw materials manufactured in the industrial, medical, electrical, aerospace, automotive, mechanical and electronic industries in Southeast Asia. These countries include Malaysia, Indonesia, Vietnam and other countries in Southeast Asia. In addition, the company is committed to developing and providing safe, effective and non-invasive liquid biopsy tests for early detection of biomarkers that the company believes are disease-related, thereby minimizing treatment costs and improving patient management. The company's non-invasive blood test provides analysis of RNA changes to detect potential risks for 11 different diseases.
Company Financials
EPS
BGLC has released its 2025 Q2 earnings. EPS was reported at -0.34, versus the expected 0, missing expectations. The chart below visualizes how BGLC has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
BGLC has released its 2025 Q2 earnings report, with revenue of 2.26M, reflecting a YoY change of 14.47%, and net profit of -616.17K, showing a YoY change of -409.47%. The Sankey diagram below clearly presents BGLC's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
